Lactation And Dermatology: Safe Medications For Breastfeeding
Essential guide to safe dermatologic treatments for breastfeeding mothers, balancing maternal skin health and infant safety.
Breastfeeding mothers with skin conditions often require dermatologic treatments, but many medications pose potential risks to the nursing infant due to transfer through breast milk. This article reviews the safety profiles of common topical and systemic dermatologic drugs during lactation, drawing on evidence from clinical guidelines and studies to recommend safer alternatives or precautions. Decisions should prioritize the benefits of breastfeeding while addressing maternal health needs on a case-by-case basis.
Who is at risk?
Women experiencing dermatologic conditions during the postpartum period and lactation are at risk. Postpartum hormonal changes, stress, sleep deprivation, and immune shifts can exacerbate or trigger skin issues such as atopic dermatitis, psoriasis, acne, eczema, or infections. Conditions like atopic eruption of pregnancy may persist into lactation, while new-onset issues like mastitis-related skin changes or hidradenitis suppurativa flares add complexity. Globally, up to 90% of postpartum women report some skin concerns, with inflammatory conditions affecting 20-50%. Infants may be indirectly affected if untreated maternal conditions lead to discomfort or interrupted breastfeeding.
Clinical findings
Safety data for dermatologic drugs in lactation derive from pharmacokinetic studies, case reports, lactation databases, and expert consensus from bodies like the American Academy of Pediatrics (AAP) and Lactation Study Center. Key considerations include drug transfer into milk (typically 1-3% of maternal dose), oral bioavailability to the infant, and half-life. Topical agents with low systemic absorption (e.g., <10%) pose minimal risk, while systemic drugs like immunosuppressants require caution. No large randomized trials exist due to ethical constraints, so recommendations rely on observational data and modeling.
Which medications are safe?
Safe medications are those with negligible milk transfer, no reported infant adverse effects, and AAP compatibility ratings. Prioritize topical over systemic where possible, and short-term use over chronic.
Topical Corticosteroids
Low- to mid-potency topical corticosteroids (TCS) like hydrocortisone (1%), fluocinolone, and triamcinolone are safe due to minimal systemic absorption (<1-5%). Excretion in breast milk is negligible, even on large areas if intermittent. Avoid potent TCS (e.g., clobetasol) on breasts or extensive areas to prevent striae or rare hypothalamic-pituitary-adrenal suppression in infants. Apply after feeds and wipe off nipples before nursing.
Topical Calcineurin Inhibitors (TCIs)
Tacrolimus and pimecrolimus have low systemic absorption (3-5%) and minimal milk transfer. Pimecrolimus is preferred for nipple eczema due to its cream base lacking paraffins that may irritate. No adverse infant effects reported; safe for limited areas.
Topical Antibiotics and Antifungals
Clindamycin, erythromycin, and mupirocin are safe topically; small amounts in milk but no infant issues. Topical metronidazole has no reported adverse effects despite manufacturer caution. For antifungals, nystatin and clotrimazole are preferred; fluconazole systemic use is discouraged.
Analgesics and NSAIDs
Ibuprofen and naproxen are AAP-approved; negligible milk levels (<0.6% dose). Indomethacin is compatible but monitor for infant GI upset.
Antihistamines
First-generation like diphenhydramine and chlorphenhydramine are safe in low doses at bedtime; may cause infant drowsiness but decrease milk supply minimally. Second-generation (loratadine, cetirizine) preferred for less sedation.
How is it diagnosed?
Diagnosis involves clinical history of breastfeeding status, skin exam, and risk assessment using tools like the LactMed database or national formularies (e.g., BNF, NZF). No specific tests; monitor infant for side effects like sedation, diarrhea, or poor weight gain post-maternal dosing.
Management
Management follows a stepwise approach: non-pharmacologic first, then safest drugs. Multidisciplinary input from dermatologists, pediatricians, and lactation consultants is ideal.
- Emollients and hygiene: Fragrance-free moisturizers (e.g., ceramide-based) and gentle cleansers are first-line for all conditions.
- Topical therapies: Limit to 2-4 weeks; smallest area possible.
- Systemic: Use only if topical fails and benefits outweigh risks; time doses after feeds.
- Pump and dump: Rarely needed; only for drugs with long half-lives like hydroxychloroquine.
Condition-Specific Recommendations
| Condition | Safe Treatments | Alternatives/Avoid |
|---|---|---|
| Atopic Dermatitis/Eczema | Hydrocortisone 1%, pimecrolimus on nipples, emollients | High-potency TCS extensive use, methotrexate |
| Psoriasis | Mid-potency TCS, calcipotriol (limited), NB-UVB phototherapy | Biologics (case-by-case), PUVA |
| Acne | Benzoyl peroxide, azelaic acid, topical erythromycin | Systemic retinoids, high-dose isotretinoin |
| Infections (bacterial) | Mupirocin, fusidic acid | Oral tetracyclines |
| Fungal | Clotrimazole, nystatin | Systemic azoles (except short fluconazole) |
Biologics and Systemic Immunomodulators
Biologics like dupilumab, ustekinumab have limited data but low milk transfer due to large molecules. Case reports show no infant harm; monitor growth. Avoid cyclosporine and methotrexate due to accumulation risks. Hydroxychloroquine is AAP-compatible in low doses.
Phototherapy
Narrowband UVB (NB-UVB) is safe; no drug excretion issues. PUVA contraindicated due to psoralen in milk causing infant photosensitivity—pump/dump 24 hours post-dose.
Investigations
Routine bloods unnecessary; consider if systemic therapy planned (e.g., LFTs for azathioprine). Infant monitoring via weight, development checks.
Possible complications
Maternal: Untreated disease worsens mental health, bonding. Infant: Rare GI upset, sedation, immunosuppression from high-risk drugs.
Prevention
Preconception counseling, maintain skin barrier with emollients during pregnancy transition.
Prognosis and follow-up
Excellent with safe alternatives; most conditions remit postpartum. Follow-up q2-4 weeks, reassess infant.
Frequently Asked Questions (FAQs)
Q: Can I use steroid creams while breastfeeding?
A: Yes, low-potency steroids like hydrocortisone are safe on limited areas; avoid potent ones on breasts. Wipe off before feeding.
Q: Are topical antibiotics safe for breastfeeding moms?
A: Yes, clindamycin and mupirocin have no reported infant issues despite trace milk levels.
Q: What about oral ibuprofen for pain?
A: Fully compatible; AAP-approved with negligible infant exposure.
Q: Is Protopic (tacrolimus) okay on nipples?
A: Pimecrolimus preferred, but tacrolimus safe sparingly; minimal absorption.
Q: Can I breastfeed on biologics like dupilumab?
A: Limited data but likely safe; consult specialist for monitoring.
Guidelines
Consult national agencies: FDA, TGA, MHRA, Medsafe, or formularies like BNF/NZF. AAP rates many dermatologic drugs compatible.
References
- Dermatological Drug Suggestions For Women Who Are Breast-feeding — Skin Therapy Letter, C. Zip, MD. 2000-01-01. https://www.skintherapyletter.com/dermatology/drug-suggestions-breast-feeding/
- Safety of dermatologic medications in pregnancy and lactation: Part … — PubMed. 2014-02-01. https://pubmed.ncbi.nlm.nih.gov/24528912/
- Safe Medical Management of Atopic Dermatitis in Pregnancy and … — EMJ Reviews. 2023-01-30. https://www.emjreviews.com/dermatology/article/safe-medical-management-of-atopic-dermatitis-in-pregnancy-and-lactation-j030123/
- Lactation and the skin – DermNet — DermNet NZ. 2023-12-01. https://dermnetnz.org/topics/lactation-and-medications-used-in-dermatology
- Biologic Use During Pregnancy and Breastfeeding in Dermatology — JDDonline. 2024-01-01. https://jddonline.com/articles/biologic-use-during-pregnancy-breastfeeding-in-dermatology-an-evidence-based-review-S1545961624P7816X
Similar Articles
Read full bio of medha deb
